Invention Grant
- Patent Title: Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
-
Application No.: US16638707Application Date: 2018-08-15
-
Publication No.: US11542255B2Publication Date: 2023-01-03
- Inventor: Matthew Cooper , David Miller , Angus MacLeod , Stephen Thom , Stephen St-Gallay , Jonathan Shannon , Thomas Alanine , Stuart Onions , Ian Strutt
- Applicant: Inflazome Limited
- Applicant Address: IE Dublin
- Assignee: Inflazome Limited
- Current Assignee: Inflazome Limited
- Current Assignee Address: IE Dublin
- Agency: Alston & Bird LLP
- Priority: GB1713082 20170815,GB1718563 20171109,GB1721726 20171222,GB1721732 20171222,GB1810983 20180704
- International Application: PCT/EP2018/072123 WO 20180815
- International Announcement: WO2019/034692 WO 20190221
- Main IPC: C07D403/12
- IPC: C07D403/12 ; C07D231/20 ; C07D401/12 ; C07D405/04 ; C07D405/12 ; C07D413/12 ; C07D471/04 ; C07D487/04

Abstract:
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
Public/Granted literature
- US20210130329A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS Public/Granted day:2021-05-06
Information query